We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Steris Warned After Data Falsification

Steris Warned After Data Falsification

June 13, 2014

Steris Corporation was warned by the FDA for several violations related to employee data manipulation and falsification.

The company’s Libertyville, Ill., facility opened an investigation in July 2013 to look into instances where product was overdosed but later made to appear within specification. However, the inspection fell short because it did not include a review of all potentially affected products, according to the May 22 warning letter posted recently online.

Steris also initiated local nonconformances for three instances of data manipulation at three separate facilities, but did not bump the issue to a corporate CAPA before the FDA’s inspection, the letter says. This would have allowed the company to address the issue across all STERIS Isomedix gamma irradiation facilities.

And while the company identified about 89 runs as possibly affected, it did not inform all identified customers that testing of their products may have been subject to data falsification, the letter adds.

The company, which sterilizes medical devices, did not adequately review its quality system in light of the data manipulation. The FDA notes that operators and material handlers were directly responsible for reading dosimeters that they placed on the product processing runs. “The analysis of the dosimeters is the primary quality control activity that determines the calculated dose for dosimeters in a gamma irradiation run and is the basis for product release,” the warning letter says.

Operators and material handlers report through operations personnel, but this created a conflict of interest when an employee reported that a run was overdosed and an operations team leader “provided guidance on how to falsify the absorbance readings so that they would appear to be within specification,” the letter says. “This reporting structure removes the Quality Unit from the ability to approve/reject irradiation runs based on dosimetry analysis and hinders the identification and correction of potential quality problems by the Quality Unit.”

The FDA said it would conduct a follow-up inspection to verify that Steris has implemented a revised procedure requiring a reading by a second independent operator.

The Oct. 29, 2013 to Jan. 8 inspection also identified 2,900 records that were missing from the main table of the company’s Dosimetry Measurement Application module between its installation at the facility on Nov. 4, 2011, and Nov. 6, 2013. “Each missing record represents an attempt at creating a dosimeter record,” the letter says, adding that “of the 2,900 missing records, 1,623 records/dosimeters … contained dosimetry data and were intentionally deleted from the DMA module.”

Other citations in the letter note that dosimeters are not routinely cleaned before analysis and an operator was seen putting an ungloved thumb on a dosimeter, thus introducing a fingerprint.

Steris has provided detailed responses to the FDA and is making improvements to the quality system at the Libertyville facility, spokesman Steve Norton said. The company does not believe the letter will have a material impact on financial results.

There’s only one way to properly record pharmaceutical data. It’s called Good Documentation Practices, and all manufacturing and lab employees with recordkeeping responsibilities need to understand and follow its rules. So purchase Good Documentation Practices today!

Medical Devices Regulatory Affairs Inspections and Audits

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing